share_log

RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $204

RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $204

RBC Capital维持瑞思迈业绩表现,将价格目标上调至$204
Benzinga ·  07/23 07:32  · 评级/大行评级

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $200 to $204.

加拿大皇家银行资本分析师Craig Wong-Pan认为,瑞思迈(纽交所:RMD)板块表现良好,将目标价格从200美元上调至204美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发